BC
KNTE

Boxer Capital’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Boxer Capital’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-491,000
Closed -$1.49M – 81
2023
Q2 		$1.49M Sell
491,000
-19,000
-4% -$73.2K 0.07% 70
2023
Q1 		$3.19M Hold
510,000
– – 0.16% 58
2022
Q4 		$3.11M Sell
510,000
-1,012,559
-67% -$8.25M 0.16% 54
2022
Q3 		$18.2M Sell
1,522,559
-325,000
-18% -$4.25M 1.02% 36
2022
Q2 		$23.3M Hold
1,847,559
– – 1.48% 25
2022
Q1 		$20.8M Hold
1,847,559
– – 1.07% 29
2021
Q4 		$32.7M Hold
1,847,559
– – 1.27% 21
2021
Q3 		$42.5M Buy
1,847,559
+781,620
+73% +$17M 1.49% 19
2021
Q2 		$24.8M Hold
1,065,939
– – 0.88% 33
2021
Q1 		$33.2M Buy
1,065,939
+1,274
+0.1% +$44.4K 1.13% 30
2020
Q4 		$42.4M Buy
+1,064,665
New +$42.7M 1.36% 21

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Boxer Capital's KNTE Position: Q3 2023 in Review

Boxer Capital sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 491,000 shares — an estimated $1.49M sold.

Boxer Capital first reported a position in KNTE in Q4 2020 and held it in 11 quarters. The position peaked at $42.5M in Q3 2021. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • Boxer Capital reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Boxer Capital sold 491,000 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $1.49M.
  • Boxer Capital first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 11 quarters.
  • Boxer Capital's Kinnate Biopharma Inc. Common Stock position peaked at $42.5M in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Boxer Capital's 13F filing for Q3 2023, filed 14 Nov 2023.